RxDoctor Payments Data

Travis Grotz, MD

Surgery · Rochester, MNNPI 1245496934

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (45.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Taiho Oncology, Inc. at 32.3% of the total. That places this record below the midpoint for surgery clinicians in MN, where the typical reported total is $1,373.

$501in general payments, 2019–2025

Across 7 payments — averaging $71.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Taiho Oncology, Inc.$162
  • Intuitive Surgical$116
  • Medtronic$113
  • AstraZeneca$110
$817,340in research payments, 2019–2025

Across 7 payments — averaging $116,763 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Iovance Biotherapeutics, Inc.$651K
  • Clinigen, Inc.$167K

What the payments were for

  • Speaking & faculty fees$20842%
  • Travel & lodging$6413%
  • Food & beverage$22946%

General payments by program year

22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Taiho Oncology, Inc.2$162
Intuitive Surgical2$116
Medtronic1$113
AstraZeneca2$110

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$501 in reported general payments places this provider in the 30th percentile of 498 surgery providers in Minnesota.

See all surgery providers in Minnesota

Medicare billing

Part B allowed, 2024
$76,320
Medicare patients
74
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neomycin Sulfate22$112
Metronidazole21$27
Ondansetron Hcl15$20

Paid to pharmacies, not to this prescriber.

Other surgery in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →